http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1110553-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5128cfc84a0fb189fceb3cd240c44493 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-501 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 |
| filingDate | 1999-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5768f9034e298248819ff6f21161585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8604f1d0f02af37f163324d2fbc4e2b |
| publicationDate | 2001-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1110553-A1 |
| titleOfInvention | Sustained release oral preparations of fasudil hydrochloride |
| abstract | Disclosed is an oral sustained-release preparationnwhich contains at least one active ingredient selectednfrom the group consisting of fasudil hydrochloride andna hydrate thereof, the preparation comprising at leastnone sustained-release coated particle comprising a corenhaving a surface and a coating formed on the surface ofnthe core, wherein the core contains the active ingredientnand the coating comprises a coating base materialnand a specific insoluble auxiliary material, and whereinnthe preparation exhibits, with respect to the activeningredient, a specific dissolution rate, as measured bynthe dissolution test. By using the oral sustained-releasenpreparation of the present invention, it becomesnpossible to surely control the release of fasudilnhydrochloride from the preparation, so that the effectnof the active ingredient is maintained for a long periodnof time. Therefore, the burden of the patient whonhas to take the preparation can be decreased and thencompliance with respect to the administration of thenpreparation can be improved. Also disclosed is anmethod for evaluating an oral sustained-release preparationncontaining the active ingredient, wherein thenevaluation is conducted with respect to the sustained-releasenability of the active ingredient. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9980972-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1550446-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020193802-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013135596-A1 |
| priorityDate | 1998-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 134.